Filing Flows › Health Care › Tactile Systems Technology (TCMD)
Tactile Systems Technology (TCMD) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 2, 2026 · Tactile Systems Technology (TCMD) Q3 2026 earnings results →
Q3 2026 Revenue up 7% year over year to $91.9M · 8¢ of every $1 of revenue kept as net profit · operating margin 10.4%
Tactile Systems Technology made $91.9M in Q3 2026 (+7% Y/Y): Lymphedema products $81.8M, Airway clearance products $10.0M. Operating margin 10.4%, net earnings $7.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $91.9M in Q3 2026, up 7% year over year and up 7% from the previous quarter. Lymphedema products was the largest line at 89% of revenue. Lymphedema products added $9.5M year over year (up 13%), 155% of the total change. Airway clearance products declined 25%.
Gross margin was 76.7%, up 0.9 points from Q3 2025. Operating profit was $9.6M, a 10.4% margin (down 2.3 points year over year). Operating profit fell $1.4M even though revenue rose $6.1M versus Q3 2025, so costs grew faster than sales. Operating expenses grew 13% against revenue growth of 7%. The fastest-growing cost line was Other operating costs (+16%). Net earnings were $7.2M, down 13% year over year. The effective tax rate was 29.3%.
Operating cash flow was $12.0M (up 16% year over year), 167% of net earnings. Non-cash charges added back $1.8M of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items added $669K. Capital expenditures of $553K left free cash flow of $11.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 2, 2026 | $91.9M | +7% | 10.4% | $7.2M | $12.0M |
| Q2 2026 | 10-Q | Aug 10, 2026 | $85.7M | +9% | 8.0% | $7.8M | $3.3M |
| Q1 2026 | 10-Q | May 4, 2026 | $75.3M | +23% | -2.0% | −$1.8M | −$339K |
| Q4 2025 | 10-K | Feb 17, 2026 | $104M | +21% | 18.1% | $10.6M | $17.3M |
| Q3 2025 | 10-Q | Nov 3, 2025 | $85.8M | +17% | 12.8% | $8.2M | $10.3M |
| Q2 2025 | 10-Q | Aug 4, 2025 | $78.9M | +8% | 5.2% | $3.2M | $14.8M |
| Q1 2025 | 10-Q | May 5, 2025 | $61.3M | +0.3% | -7.4% | −$3.0M | $417K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 51% of its revenue · Stated in 10-K (sentence) · source
About Tactile Systems Technology
Tactile Systems Technology, Inc. (“we,” “us,” and “our”) is a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. and in September 2013, we began doing business as “Tactile Medical”.
In its own words, from its 10-K, filed Feb 17, 2026.
Tactile Systems Technology against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +7% against the peers' median +5%. Operating margin: 10.4% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TCMD Tactile Systems Technology | Q3 2026 | $91.9M | +7% | 10.4% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Tactile Systems Technology 10-Q on SEC EDGAR · CIK 1027838 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns TCMD and who is buying
More on TCMD
- How Tactile Systems Technology makes money: revenue by segment
- Tactile Systems Technology next earnings date and what analysts expect
- Tactile Systems Technology stock forecast, price target and fair value
- Who owns Tactile Systems Technology stock: holders, funds and Congress trades
- Tactile Systems Technology guidance and outlook
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Tactile Systems Technology guidance history: guided vs reported
- Tactile Systems Technology gross margin by quarter
- Tactile Systems Technology operating margin by quarter
- Tactile Systems Technology net income by quarter
- Tactile Systems Technology free cash flow by quarter
- Tactile Systems Technology R&D spending by quarter
- Tactile Systems Technology capital expenditures by quarter
- Tactile Systems Technology Lymphedema products revenue by quarter
- Tactile Systems Technology Airway clearance products revenue by quarter